Fiasp approved for children in Europe
Novo Nordisk submitted label updates in March this year.
Read More
Tag: Fiasp
EU nod for Novo’s new fast-acting insulin
European regulators have approved Novo Nordisk’s fast acting insulin Fiasp for the treatment of diabetes in adults, as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via a pump.
Read More
Nine therapies put forward for EU approval
Nine therapies spanning a range of diseases have been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including three biosimilars and two diabetes drugs.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
